Biospecifics Technologies Corp. (BSTC)
Stock Price:
$63.87 USD
-0.44 (-0.68%)
Updated Aug 4, 2020 3:29 PM EDT - Market open
Key Info
| Market Cap |
469.12M |
| Revenue (ttm) |
39.73M |
| Net Income (ttm) |
24.55M |
| Shares Out |
7.34M |
| EPS (ttm) |
3.34 |
| PE Ratio |
19.12 |
| Forward PE |
30.58 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$63.87 |
| Previous Close |
$64.31 |
| Change ($) |
-0.44 |
| Change (%) |
-0.68% |
| Day's Open |
64.32 |
| Day's Range |
62.39 - 64.76 |
| Day's Volume |
25,399 |
| 52-Week Range |
42.00 - 69.51 |
More Stats
| Market Cap |
469.12M |
| Enterprise Value |
365.13M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
7.34M |
| Float |
4.31M |
| EPS (basic) |
3.36 |
| EPS (diluted) |
3.34 |
| FCF / Share |
3.33 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
5.23% |
| FCF Yield |
5.20% |
| Payout Ratio |
n/a |
| Shares Short |
298,977 |
| Short Ratio |
7.08 |
| Short % of Float |
4.55% |
| Beta |
0.90 |
| PE Ratio |
19.12 |
| Forward PE |
30.58 |
| P/FCF Ratio |
19.23 |
| PS Ratio |
11.81 |
| PB Ratio |
3.56 |
| Revenue |
39.73M |
| Operating Income |
28.47M |
| Net Income |
24.55M |
| Free Cash Flow |
24.40M |
| Net Cash |
103.99M |
| Net Cash / Share |
14.16 |
| Gross Margin |
96.12% |
| Operating Margin |
71.67% |
| Profit Margin |
61.80% |
| FCF Margin |
61.41% |
| ROA |
15.48% |
| ROE |
21.21% |
| ROIC |
28.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
100
Current: $63.87
High
100
Target: 100.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 38.19 | 32.96 | 27.44 | 26.25 | 22.75 | 14.04 | 14.43 | 11.15 | 11.40 | 5.66 |
| Revenue Growth | 15.86% | 20.11% | 4.54% | 15.39% | 61.98% | -2.67% | 29.47% | -2.2% | 101.29% | - |
| Gross Profit | 38.19 | 32.96 | 27.44 | 26.25 | 22.75 | 14.04 | 14.43 | 11.15 | 11.40 | 5.66 |
| Operating Income | 28.31 | 23.40 | 17.68 | 17.03 | 14.44 | 6.97 | 7.91 | 5.12 | 5.19 | -2.03 |
| Net Income | 24.47 | 20.05 | 11.33 | 11.37 | 9.62 | 4.65 | 5.29 | 2.98 | 6.60 | -1.51 |
| Shares Outstanding | 7.32 | 7.24 | 7.17 | 7.06 | 6.83 | 6.48 | 6.35 | 6.35 | 6.34 | 6.26 |
| Earnings Per Share | 3.33 | 2.73 | 1.55 | 1.56 | 1.32 | 0.66 | 0.76 | 0.43 | 0.95 | -0.24 |
| EPS Growth | 21.98% | 76.13% | -0.64% | 18.18% | 100% | -13.16% | 76.74% | -54.74% | - | - |
| Operating Cash Flow | 22.29 | 17.73 | 13.16 | 16.35 | 10.61 | 6.13 | 4.54 | 0.93 | -0.69 | -0.88 |
| Capital Expenditures | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | 22.29 | 17.73 | 13.16 | 16.35 | 10.61 | 6.13 | 4.54 | 0.93 | -0.69 | -0.88 |
| Cash & Equivalents | 89.24 | 80.88 | 59.31 | 49.02 | 33.49 | 20.71 | 12.59 | 8.50 | 8.20 | 7.83 |
| Total Debt | 0.24 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 89.00 | 80.88 | 59.31 | 49.02 | 33.49 | 20.71 | 12.59 | 8.50 | 8.20 | 7.83 |
| Assets | 127 | 100 | 75.00 | 64.70 | 45.70 | 31.03 | 23.25 | 18.39 | 16.27 | 11.52 |
| Liabilities | 2.16 | 2.50 | 7.48 | 8.41 | 0.89 | 0.77 | 0.92 | 0.93 | 1.39 | 4.82 |
| Book Value | 124 | 97.59 | 67.52 | 56.28 | 44.81 | 30.26 | 22.33 | 17.46 | 14.87 | 6.70 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Biospecifics Technologies Corp. |
| Country |
United States |
| Employees |
7 |
| CEO |
Joseph Truitt |
Stock Information
| Ticker Symbol |
BSTC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: BSTC |
| IPO Date |
November 14, 1991 |
Description
BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.